OVID Stock Soars 40% in 2 Sessions on Preliminary Drug Results

OVID stock

OVID stock is one of the biggest penny stock gainers in the biotech sector this week after Ovid Therapeutics Inc (NASDAQ:OVID) reported preliminary results from a Phase 2 open-label extension study.

Positive Momentum

Ovid Therapeutics has been one of the more interesting companies in the therapeutics space this year and has made important strides as a business so far. In a new development, the company yesterday announced that it has received the preliminary results from the Phase 2 study of its product OV925/TAK-935 or soticlestat.

The tests have been performed on patients for up ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.